Immune Reconstitution to Measles Virus of HIV-1-Infected Zambian Children Initiating Antiretroviral Therapy View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2012

ABSTRACT

This is an observational study of HIV-1 infected children starting antiretroviral therapy to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. Detailed Description This is a prospective, observational cohort study of 230 HIV-1-infected children initiating ART at public clinics in Lusaka, Zambia to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. Non-specific immune reconstitution will be assessed by serial measurements of the number and percentages of CD4+ and CD8+ T-lymphocytes, number and percentages of activated CD4+ and CD8+ T-lymphocytes (using cell surface staining for HLA-DR and CD38), changes in the proportions of naïve and memory CD4+ and CD8+ T-lymphocyte subsets (using cell surface staining for CD45RA and CCR7), and changes in thymic output as determined by TREC levels. Virologic responses to ART will be assessed by serial measurements of plasma HIV-1 RNA levels.Within the observational study, there is a nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers to assess the proportion of revaccinated children who develop protective immunity and the duration of protective immunity. Anti-measles virus IgG antibodies will be measured 9 months after initiation of ART. The results will be available at the 12-month follow-up visit and measles revaccination will be recommended to those children lacking protective antibody levels to measles virus. More... »

URL

https://clinicaltrials.gov/show/NCT02058927

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This is an observational study of HIV-1 infected children starting antiretroviral therapy to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus.\n\nDetailed Description\nThis is a prospective, observational cohort study of 230 HIV-1-infected children initiating ART at public clinics in Lusaka, Zambia to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. Non-specific immune reconstitution will be assessed by serial measurements of the number and percentages of CD4+ and CD8+ T-lymphocytes, number and percentages of activated CD4+ and CD8+ T-lymphocytes (using cell surface staining for HLA-DR and CD38), changes in the proportions of na\u00efve and memory CD4+ and CD8+ T-lymphocyte subsets (using cell surface staining for CD45RA and CCR7), and changes in thymic output as determined by TREC levels. Virologic responses to ART will be assessed by serial measurements of plasma HIV-1 RNA levels.Within the observational study, there is a nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers to assess the proportion of revaccinated children who develop protective immunity and the duration of protective immunity. Anti-measles virus IgG antibodies will be measured 9 months after initiation of ART. The results will be available at the 12-month follow-up visit and measles revaccination will be recommended to those children lacking protective antibody levels to measles virus.", 
    "endDate": "2012-02", 
    "id": "sg:clinicaltrial.NCT02058927", 
    "keywords": [
      "HIV-1-infected children", 
      "immune reconstitution", 
      "measles virus", 
      "antiretroviral therapy", 
      "protective immunity", 
      "T lymphocytes", 
      "observational study", 
      "serial measurements", 
      "plasma HIV-1 RNA levels", 
      "HIV-1 RNA levels", 
      "initiation of ART", 
      "protective antibody levels", 
      "protective antibody titers", 
      "percentage of CD4", 
      "observational cohort study", 
      "T lymphocyte subsets", 
      "proportion of na\u00efve", 
      "TREC levels", 
      "measles revaccination", 
      "virologic response", 
      "cohort study", 
      "memory CD4", 
      "thymic output", 
      "antibody levels", 
      "antibody titers", 
      "IgG antibodies", 
      "Zambian children", 
      "HIV-1", 
      "public clinics", 
      "CD8", 
      "CD4", 
      "RNA levels", 
      "revaccination", 
      "virus", 
      "children", 
      "therapy", 
      "immunity", 
      "reconstitution", 
      "clinic", 
      "follow", 
      "levels", 
      "proportion", 
      "study", 
      "percentage", 
      "titers", 
      "visits", 
      "months", 
      "antibodies", 
      "na\u00efve", 
      "Lusaka", 
      "duration", 
      "changes", 
      "initiation", 
      "subset", 
      "response", 
      "quality", 
      "number", 
      "Zambia", 
      "measurements", 
      "results", 
      "magnitude", 
      "detailed description", 
      "output", 
      "description", 
      "art"
    ], 
    "name": "Immune Reconstitution to Measles Virus of HIV-1-Infected Zambian Children Initiating Antiretroviral Therapy", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02058927"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2022-10-01T07:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/clinical_trial/clinical_trial_1.jsonl", 
    "sponsor": [
      {
        "id": "http://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-05", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/nature01318", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048417003", 
          "https://doi.org/10.1038/nature01318"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10875-006-9008-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040695715", 
          "https://doi.org/10.1007/s10875-006-9008-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04651", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024462310", 
          "https://doi.org/10.1038/nature04651"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature01441", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038925353", 
          "https://doi.org/10.1038/nature01441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ni1009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030659779", 
          "https://doi.org/10.1038/ni1009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm0298-208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046625046", 
          "https://doi.org/10.1038/nm0298-208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ni1105", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002688434", 
          "https://doi.org/10.1038/ni1105"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02058927"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02058927'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02058927'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02058927'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02058927'


 

This table displays all metadata directly associated to this object as RDF triples.

118 TRIPLES      16 PREDICATES      89 URIs      74 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02058927 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1107
4 schema:description This is an observational study of HIV-1 infected children starting antiretroviral therapy to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. Detailed Description This is a prospective, observational cohort study of 230 HIV-1-infected children initiating ART at public clinics in Lusaka, Zambia to measure the magnitude and quality of general immune reconstitution and pathogen-specific immune reconstitution to measles virus. Non-specific immune reconstitution will be assessed by serial measurements of the number and percentages of CD4+ and CD8+ T-lymphocytes, number and percentages of activated CD4+ and CD8+ T-lymphocytes (using cell surface staining for HLA-DR and CD38), changes in the proportions of naïve and memory CD4+ and CD8+ T-lymphocyte subsets (using cell surface staining for CD45RA and CCR7), and changes in thymic output as determined by TREC levels. Virologic responses to ART will be assessed by serial measurements of plasma HIV-1 RNA levels.Within the observational study, there is a nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers to assess the proportion of revaccinated children who develop protective immunity and the duration of protective immunity. Anti-measles virus IgG antibodies will be measured 9 months after initiation of ART. The results will be available at the 12-month follow-up visit and measles revaccination will be recommended to those children lacking protective antibody levels to measles virus.
5 schema:endDate 2012-02
6 schema:keywords CD4
7 CD8
8 HIV-1
9 HIV-1 RNA levels
10 HIV-1-infected children
11 IgG antibodies
12 Lusaka
13 RNA levels
14 T lymphocyte subsets
15 T lymphocytes
16 TREC levels
17 Zambia
18 Zambian children
19 antibodies
20 antibody levels
21 antibody titers
22 antiretroviral therapy
23 art
24 changes
25 children
26 clinic
27 cohort study
28 description
29 detailed description
30 duration
31 follow
32 immune reconstitution
33 immunity
34 initiation
35 initiation of ART
36 levels
37 magnitude
38 measles revaccination
39 measles virus
40 measurements
41 memory CD4
42 months
43 naïve
44 number
45 observational cohort study
46 observational study
47 output
48 percentage
49 percentage of CD4
50 plasma HIV-1 RNA levels
51 proportion
52 proportion of naïve
53 protective antibody levels
54 protective antibody titers
55 protective immunity
56 public clinics
57 quality
58 reconstitution
59 response
60 results
61 revaccination
62 serial measurements
63 study
64 subset
65 therapy
66 thymic output
67 titers
68 virologic response
69 virus
70 visits
71 schema:name Immune Reconstitution to Measles Virus of HIV-1-Infected Zambian Children Initiating Antiretroviral Therapy
72 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02058927
73 schema:sdDatePublished 2022-10-01T07:01
74 schema:sdLicense https://scigraph.springernature.com/explorer/license/
75 schema:sdPublisher N68ee3d16e44c4399b60bbae09f367c07
76 schema:sponsor grid-institutes:grid.419681.3
77 schema:startDate 2011-05
78 schema:subjectOf sg:pub.10.1007/s10875-006-9008-4
79 sg:pub.10.1038/nature01318
80 sg:pub.10.1038/nature01441
81 sg:pub.10.1038/nature04651
82 sg:pub.10.1038/ni1009
83 sg:pub.10.1038/ni1105
84 sg:pub.10.1038/nm0298-208
85 schema:url https://clinicaltrials.gov/show/NCT02058927
86 sgo:license sg:explorer/license/
87 sgo:sdDataset clinical_trials
88 rdf:type schema:MedicalStudy
89 N68ee3d16e44c4399b60bbae09f367c07 schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
92 rdf:type schema:DefinedTerm
93 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
94 rdf:type schema:DefinedTerm
95 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
96 rdf:type schema:DefinedTerm
97 sg:pub.10.1007/s10875-006-9008-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040695715
98 https://doi.org/10.1007/s10875-006-9008-4
99 rdf:type schema:CreativeWork
100 sg:pub.10.1038/nature01318 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048417003
101 https://doi.org/10.1038/nature01318
102 rdf:type schema:CreativeWork
103 sg:pub.10.1038/nature01441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038925353
104 https://doi.org/10.1038/nature01441
105 rdf:type schema:CreativeWork
106 sg:pub.10.1038/nature04651 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024462310
107 https://doi.org/10.1038/nature04651
108 rdf:type schema:CreativeWork
109 sg:pub.10.1038/ni1009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030659779
110 https://doi.org/10.1038/ni1009
111 rdf:type schema:CreativeWork
112 sg:pub.10.1038/ni1105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002688434
113 https://doi.org/10.1038/ni1105
114 rdf:type schema:CreativeWork
115 sg:pub.10.1038/nm0298-208 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046625046
116 https://doi.org/10.1038/nm0298-208
117 rdf:type schema:CreativeWork
118 grid-institutes:grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...